PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.03
D/E of 0.03 versus zero Biotechnology median. Walter Schloss would verify if our leverage provides competitive advantages.
2.11
Higher net debt at 1.1-1.25x Biotechnology median of 1.79. John Neff would demand higher growth rates to justify this leverage premium.
-36.71
Negative coverage while Biotechnology median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
2.36
Current ratio below 50% of Biotechnology median of 4.99. Michael Burry would check for immediate refinancing needs.
No Data
No Data available this quarter, please select a different quarter.